Abstract
Ductal carcinoma in situ (DCIS) represents a spectrum of abnormal cells confined to the breast and is a risk factor for invasive cancer development. The incidence has increased dramatically in recent years as a result of widespread use of screening mammography. Given the lack of clarity and the incomplete data regarding the natural history, prognostic factors, and biology of DCIS, important therapeutic questions remain unanswered. Currently, patient age, size of the lesion, nuclear grade, comedonecrosis, and the margin width are accepted as the major parameters for treatment decision. In this chapter, treatment approach for patients with DCIS and the role of radiotherapy will be discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Marta GN, Hanna SA, Martella E. Early stage breast cancer and radiotherapy: update. Rev Assoc Med Bras. 2011;57:459–64.
Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999;85:616–28.
Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77:2267–74.
Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186:337–43.
Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–18.
EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853–a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;26:3381–7.
Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21–9.
Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162–77.
Post-operative radiotherapy for ductal carcinoma in situ of the breast(Review) Copyright © 2009 The Cochrane Collaboration. Published by Wiley; 2009.
Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24:1031–6.
Hughes LL, Wang M, Page D, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the eastern cooperative oncology group. J Clin Oncol. 2009;27:5319–24.
Motwani SB, Goyal S, Moran MS, Chhabra A, Haffty BG. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194. Cancer. 2011;117:1156–62.
Goyal S, Vicini F, Beitsch PD, et al. Ductal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite registry trial with intergroup study E5194. Cancer. 2011;115:1149–55.
Lari AS, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232–61.
Solin L. The impact of adding radiation treatment after breast conservation surgery for ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;41:187–92.
Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001.
Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New Engl J Med. 2001;345:1378–87.
Azria D, Auvray H, Barillot I, et al. Ductal carcinoma in situ: role of the boost. Cancer Radiother. 2008;12:571–6.
Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol. 2006;7:652–6.
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.
Taghian AG, Smith BL, Erban JK. Breast cancer a multidiciplinary approach to diagnosis and treatment. 1st ed. NewYork: Demos Medical Publishing; 2010.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bese, N.S., Ay, A. (2013). Ductal Carcinoma In Situ. In: Haydaroglu, A., Ozyigit, G. (eds) Principles and Practice of Modern Radiotherapy Techniques in Breast Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5116-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5116-7_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5115-0
Online ISBN: 978-1-4614-5116-7
eBook Packages: MedicineMedicine (R0)